Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1969 1
1976 1
1979 1
1983 1
1985 3
1986 1
1988 2
1990 1
1992 1
1993 2
1994 2
1995 7
1996 3
1997 4
1999 4
2000 2
2001 1
2002 2
2003 5
2004 1
2005 7
2006 2
2007 4
2008 5
2009 5
2010 6
2011 8
2012 21
2013 29
2014 27
2015 23
2016 25
2017 29
2018 33
2019 23
2020 31
2021 55
2022 52
2023 55
2024 66
2025 73
2026 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

597 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Platinum-etoposide consisted of etoposide 80-100 mg/m(2) on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m(2) (administered on day 1 of each cycle). ...
Platinum-etoposide consisted of etoposide 80-100 mg/m(2) on days 1-3 of each cycle with investigator's choice of either carboplatin a …
Engineering RNA export for measurement and manipulation of living cells.
Horns F, Martinez JA, Fan C, Haque M, Linton JM, Tobin V, Santat L, Maggiolo AO, Bjorkman PJ, Lois C, Elowitz MB. Horns F, et al. Cell. 2023 Aug 17;186(17):3642-3658.e32. doi: 10.1016/j.cell.2023.06.013. Epub 2023 Jul 11. Cell. 2023. PMID: 37437570 Free PMC article.
DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism.
Jee J, Brannon AR, Singh R, Derkach A, Fong C, Lee A, Gray L, Pichotta K, Luthra A, Diosdado M, Haque M, Guo J, Hernandez J, Garg K, Wilhelm C, Arcila ME, Pavlakis N, Clarke S, Shah SP, Razavi P, Reis-Filho JS, Ladanyi M, Schultz N, Zwicker J, Berger MF, Li BT, Mantha S. Jee J, et al. Nat Med. 2024 Sep;30(9):2499-2507. doi: 10.1038/s41591-024-03195-0. Epub 2024 Aug 15. Nat Med. 2024. PMID: 39147831 Free PMC article.
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Demographics Collaborators. GBD 2021 Demographics Collaborators. Lancet. 2024 May 18;403(10440):1989-2056. doi: 10.1016/S0140-6736(24)00476-8. Epub 2024 Mar 11. Lancet. 2024. PMID: 38484753 Free PMC article.
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.
Tchekmedyian V, Sherman EJ, Dunn L, Tran C, Baxi S, Katabi N, Antonescu CR, Ostrovnaya I, Haque SS, Pfister DG, Ho AL. Tchekmedyian V, et al. J Clin Oncol. 2019 Jun 20;37(18):1529-1537. doi: 10.1200/JCO.18.01859. Epub 2019 Apr 2. J Clin Oncol. 2019. PMID: 30939095 Free PMC article. Clinical Trial.
PURPOSE: Recurrent or metastatic adenoid cystic carcinoma (R/M ACC) is a malignant neoplasm of predominantly salivary gland origin for which effective therapies are lacking. ...Patients with histologically confirmed R/M ACC of any primary site with radiographic and/ …
PURPOSE: Recurrent or metastatic adenoid cystic carcinoma (R/M ACC) is a malignant neoplasm of predominantly salivary gland origin fo …
597 results